Peripheral Ulcerative Keratopathy following Systemic Treatment with Bortezomib: A Case Report

ABSTRACT

A 60-year-old patient was diagnosed with multiple myeloma in November 2020, and started treatment in December 2020 with bortezomib, dexamethasone, and thalidomide. Four months later, he presented to the ophthalmology emergency department with inflammation and pain in the left eye. Examination of the anterior segment revealed severe, mixed anterior squamous blepharitis with significant bilateral palpebral inflammation, dysfunction of the meibomian glands, and several styes on both eyelids bilaterally. A peripheral ulcerative keratopathy was detected while examining the left eye cornea, with an inferior infiltrate and significant thinning, approximately 5 mm in length, at the limbal margin (Figure 1). Tear break-up time was shortened bilaterally. In addition to palpebral hygiene and oral treatment with doxycycline 100 mg every 24 hours, the patient was prescribed the following topical treatment without preservatives: artificial tears with lipid emulsion, netilmicin 0,3% 0,4 ml eye drops every 6 hours and dexamethasone 1 mg/ml every 8 hours.

KEYWORDS:

• Bortezomib
• case report
• chemotherapy
• ulcerative keratopathy

Disclosure statement

The authors report there are no competing interests to declare.

Informed consent

Informed consent read and signed by the patient.

Additional information

Funding

Edition of the article has been financed by RETICS OFTARED “RD 16/0008/0010,” financed by the Instituto de Salud Carlos III, as part of the Plan Nacional i+D+I and co-financed by European Union (FEDER/FSE): Una manera de hacer Europa 2013-2016.